05:22 AM EDT, 07/24/2026 (MT Newswires) -- Aoti (AOTI.L) noted the US Centers for Medicare & Medicaid Services' proposed Local Coverage Determination, or LCD, for topical oxygen therapy in the treatment of diabetic foot ulcers, potentially boosting the company's addressable market in the country. The medical technology company said Friday that a final LCD, which would establish nationwide Medicare reimbursement criteria for its topical wound oxygen therapy, could bolster its momentum and revenue stream. The proposal will enter a 45-day public comment period, after which the federal agency will review and finalize the determination within a year.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.